Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Astellas Prepares Applications for 2 Products, Discontinues Development of 6
February 14, 2011
- Otsuka to Start PII Trial of OCV-101 for Pancreatic Cancer
February 14, 2011
- PhRMA to Call For Full Introduction of Premium for Development of New Drugs: Mr Umeda
February 14, 2011
- Gov't to Accept Court-Proposed Compromise in Lawsuit over Hepatitis B
February 14, 2011
- Bayer, Regeneron Start PIII Trial of VEGF Trap-Eye in mCNV in Japan
February 14, 2011
- Approval of Norspan Withheld to Ensure Proper Use: Prof. Ogawa
February 14, 2011
- Sekisui Begins Diagnostics Business Acquired from Genzyme
February 14, 2011
- PIII Trial Confirms Long-Term Safety Profile of Latuda
February 14, 2011
- It Was Necessary to Invite Comments from Public on Approval of NorLevo: Korosho
February 14, 2011
- Dispensing Fee per Prescription Down 1% in 1st Five Months of FY2010
February 14, 2011
- Dr Teshirogi Calls on Doctors to Cooperate to Obtain More Financial Resources for Healthcare
February 7, 2011
- MTPC Applies for MP-424 in Japan
February 7, 2011
- Takeda Begins PIII Trial of AMG 386 in Japan
February 7, 2011
- MTPC Shipped 4 Injectables without Conducting Necessary Quality Tests
February 7, 2011
- Novartis Applies for Canakinumab for CAPS
February 7, 2011
- Insight Obtained into Mechanism of Nerve Cell Protection Following Cerebral Infarction
February 7, 2011
- Top-4 Wholesalers Report Slow Price Settlement, Difficulty in Reducing Yakkasa
February 7, 2011
- Eisai Won't Seek Regulatory Approval for Eritoran in March
February 7, 2011
- Peretinoin Reduces Risk of HCC Recurrence or Death
February 7, 2011
- JACDS Calls on Its Members to Refrain from Offering Points for Dispensing Services
February 7, 2011
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…